Tags

Type your tag names separated by a space and hit enter

Oral simvastatin treatment in relapsing-remitting multiple sclerosis.

Abstract

Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA.

    , , , , , , ,

    Source

    Lancet (London, England) 363:9421 2004 May 15 pg 1607-8

    MeSH

    Adjuvants, Immunologic
    Administration, Oral
    Adolescent
    Adult
    Brain
    Contrast Media
    Female
    Gadolinium
    Humans
    Magnetic Resonance Imaging
    Male
    Middle Aged
    Multiple Sclerosis, Relapsing-Remitting
    Simvastatin

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15145635

    Citation

    Vollmer, Timothy, et al. "Oral Simvastatin Treatment in Relapsing-remitting Multiple Sclerosis." Lancet (London, England), vol. 363, no. 9421, 2004, pp. 1607-8.
    Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607-8.
    Vollmer, T., Key, L., Durkalski, V., Tyor, W., Corboy, J., Markovic-Plese, S., ... Singh, I. (2004). Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (London, England), 363(9421), pp. 1607-8.
    Vollmer T, et al. Oral Simvastatin Treatment in Relapsing-remitting Multiple Sclerosis. Lancet. 2004 May 15;363(9421):1607-8. PubMed PMID: 15145635.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Oral simvastatin treatment in relapsing-remitting multiple sclerosis. AU - Vollmer,Timothy, AU - Key,Lyndon, AU - Durkalski,Valerie, AU - Tyor,William, AU - Corboy,John, AU - Markovic-Plese,Silva, AU - Preiningerova,Jana, AU - Rizzo,Marco, AU - Singh,Inderjit, PY - 2004/5/18/pubmed PY - 2004/5/28/medline PY - 2004/5/18/entrez SP - 1607 EP - 8 JF - Lancet (London, England) JO - Lancet VL - 363 IS - 9421 N2 - Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability. SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/15145635/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(04)16205-3 DB - PRIME DP - Unbound Medicine ER -